Cubist Systematic Strategies LLC Purchases New Shares in Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 9,271 shares of the biotechnology company’s stock, valued at approximately $79,000. Cubist Systematic Strategies LLC owned approximately 0.19% of Atara Biotherapeutics as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Point72 Asia Singapore Pte. Ltd. bought a new stake in Atara Biotherapeutics in the second quarter worth approximately $53,000. Price T Rowe Associates Inc. MD boosted its holdings in Atara Biotherapeutics by 8,916.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 4,958,150 shares of the biotechnology company’s stock valued at $3,442,000 after purchasing an additional 4,903,159 shares in the last quarter. Redmile Group LLC grew its position in Atara Biotherapeutics by 1.7% in the first quarter. Redmile Group LLC now owns 9,263,309 shares of the biotechnology company’s stock valued at $6,429,000 after acquiring an additional 156,863 shares during the period. Acadian Asset Management LLC increased its position in shares of Atara Biotherapeutics by 49.5% during the 1st quarter. Acadian Asset Management LLC now owns 2,638,687 shares of the biotechnology company’s stock worth $1,830,000 after purchasing an additional 873,133 shares in the last quarter. Finally, BNP Paribas Financial Markets increased its holdings in shares of Atara Biotherapeutics by 29.3% during the first quarter. BNP Paribas Financial Markets now owns 383,082 shares of the biotechnology company’s stock worth $266,000 after buying an additional 86,842 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

Atara Biotherapeutics Trading Up 2.8 %

ATRA stock opened at $8.38 on Wednesday. Atara Biotherapeutics, Inc. has a 1-year low of $4.96 and a 1-year high of $40.92. The business’s 50 day simple moving average is $7.81 and its 200 day simple moving average is $11.49. The firm has a market capitalization of $40.37 million, a PE ratio of -0.16 and a beta of 0.50.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its quarterly earnings data on Monday, August 12th. The biotechnology company reported ($3.10) earnings per share for the quarter, missing the consensus estimate of ($1.56) by ($1.54). The firm had revenue of $28.64 million for the quarter, compared to the consensus estimate of $48.30 million. As a group, sell-side analysts predict that Atara Biotherapeutics, Inc. will post -12.09 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on the company. HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a research report on Wednesday, August 21st. StockNews.com assumed coverage on shares of Atara Biotherapeutics in a research report on Wednesday, June 26th. They issued a “hold” rating on the stock. The Goldman Sachs Group reduced their price target on Atara Biotherapeutics from $12.50 to $11.00 and set a “sell” rating for the company in a research report on Wednesday, July 17th. Mizuho upgraded Atara Biotherapeutics from a “neutral” rating to an “outperform” rating and decreased their price objective for the company from $25.00 to $18.00 in a report on Friday, August 16th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $13.00 target price on shares of Atara Biotherapeutics in a report on Tuesday, August 13th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, Atara Biotherapeutics presently has a consensus rating of “Hold” and an average target price of $14.00.

Atara Biotherapeutics Profile

Atara Biotherapeutics, Inc develops therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.